Melinda L. Telli, MD, of the Stanford Cancer Institute, discusses the various systemic therapies for patients with early-stage hormone receptor–positive, HER2-negative disease.
Melinda Telli, MD, of the Stanford University School of Medicine, discusses the current status of treatment for advanced TNBC, and new therapeutic strategies now being used for better outcomes.
Melinda Telli, MD, of Stanford Cancer Institute, discusses the TNT trial for triple-negative breast cancer and the results reported at the San Antonio Breast Cancer Symposium.
In the phase II PrECOG 0105 study reported in the Journal of Clinical Oncology, Telli et al found that neoadjuvant iniparib plus gemcitabine-carboplatin was active in early-stage triple-negative and BRCA1/2-mutant breast cancer. Higher score on a homologous recombination deficiency–loss of...